Spontaneous reports of vasculitis as an adverse event following immunization: A descriptive analysis across three international databases

Vaccine

Volumn 34, Issue 51, 2016, Pages 6634-6640

  Felicetti, Patrizia ^a   Trotta, Francesco ^a   Bonetto, Caterina ^a   Santuccio, Carmela ^a   Brauchli Pernus, Yolanda ^b   Burgner, David ^c,d   Chandler, Rebecca ^e   Girolomoni, Giampiero ^f   Hadden, Robert D M ^g   Kochar, Sonali ^h   Kucuku, Merita ⁱ   Monaco, Giuseppe ^j   Ozen, Seza ^k   Pahud, Barbara ^l   Phuong, Linny ^m   Bachtiar, Novilia Sjafri ⁿ   Teeba, Amina ^o   Top, Karina ^p   Varricchio, Frederick ^q   Wise, Robert P ^r   Zanoni, Giovanna ^s   Živkovic, Saša ^t   Bonhoeffer, Jan ^b,u   more..

^a ITALIAN MEDICINES AGENCY   (Italy)

^b Brighton Collaboration Foundation   (Switzerland)

^c MONASH CHILDREN S HOSPITAL   (Australia)

^d UNIVERSITY OF MELBOURNE   (Australia)

^e UPPSALA MONITORING CENTRE   (Sweden)

^f UNIVERSITY OF VERONA   (Italy)

^g KING S COLLEGE HOSPITAL   (United Kingdom)

^h Deliver Project   (India)

ⁱ National Agency for Medicine Medical Devices   (Albania)

^j Regional Center for Pharmacovigilance   (Italy)

^k HACETTEPE UNIVERSITY   (Turkey)

^l CHILDREN S MERCY HOSPITAL   (United States)

^m MONASH CHILDREN S HOSPITAL   (Australia)

ⁿ Bio Farma   (Indonesia)

^o Centre Anti poison   (Morocco)

^p DALHOUSIE UNIVERSITY   (Canada)

^q Independent Consultant Vaccinologist   (United States)

^r MEDIMMUNE   (United States)

^s UNIVERSITY HOSPITAL OF VERONA   (Italy)

^t UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

^u UNIVERSITY CHILDREN S HOSPITAL   (Switzerland)

more..

Author keywords

Adverse event following immunization (AEFI); Eudravigilance; Immunization; Pharmacovigilance; Spontaneous reporting; Vaccines; VAERS; Vasculitis; VigiBase

Indexed keywords

BACTERIAL VACCINE; ENCEPHALITIS VACCINE; HAEMOPHILUS INFLUENZAE VACCINE; HEPATITIS VACCINE; INFLUENZA VACCINE; MEASLES VACCINE; MENINGOCOCCUS VACCINE; PNEUMOCOCCUS VACCINE; ROTAVIRUS VACCINE; TETANUS TOXOID; VACCINE; VARICELLA ZOSTER VACCINE; VIRUS VACCINE; WART VIRUS VACCINE; YELLOW FEVER VACCINE;

ADOLESCENT; ADULT; AGED; ANAPHYLACTOID PURPURA; ARTERITIS; ARTICLE; BACTERIAL INFECTION; BEHCET DISEASE; BRAIN VASCULITIS; CENTRAL NERVOUS SYSTEM DISEASE; CHILD; CHURG STRAUSS SYNDROME; CONTROLLED STUDY; ENCEPHALITIS; FEMALE; GRANULOMATOSIS; HAEMOPHILUS INFECTION; HEPATITIS; HERPES ZOSTER; HUMAN; HYPERSENSITIVITY; INFANT; INFLUENZA; MAJOR CLINICAL STUDY; MALE; MEASLES; MENINGOCOCCOSIS; MIDDLE AGED; MUCOCUTANEOUS LYMPH NODE SYNDROME; NEWBORN; PAPILLOMAVIRUS INFECTION; PNEUMOCOCCAL INFECTION; POLYARTERITIS NODOSA; PRESCHOOL CHILD; PRIORITY JOURNAL; PURPURA; RHEUMATIC POLYMYALGIA; ROTAVIRUS INFECTION; SCHOOL CHILD; SKIN DISEASE; SKIN TUBERCULOSIS; TEMPORAL ARTERITIS; TETANUS; VACCINATION; VASCULITIC RASH; VASCULITIS; VIRUS INFECTION; YELLOW FEVER; YOUNG ADULT; CHEMICALLY INDUCED; DRUG SURVEILLANCE PROGRAM; FACTUAL DATABASE; GLOBAL HEALTH; IMMUNIZATION; PREVALENCE; VERY ELDERLY;

ADOLESCENT; ADULT; ADVERSE DRUG REACTION REPORTING SYSTEMS; AGED; AGED, 80 AND OVER; CHILD; CHILD, PRESCHOOL; DATABASES, FACTUAL; FEMALE; GLOBAL HEALTH; HUMANS; IMMUNIZATION; INFANT; INFANT, NEWBORN; MALE; MIDDLE AGED; PREVALENCE; VASCULITIS; YOUNG ADULT;

EID: 85001052507     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2015.09.027     Document Type: Article

References (28)

1. [1] Watts, R.A., Suppiah, R., Merkel, P.A., Luqmani, R., Systemic vasculitis—is it time to reclassify?. Rheumatology 50:4 (2011), 643–645.
2. [2] Waller, R., Ahmed, A., Patel, I., Luqmani, R., Update on the classification of vasculitis. Best Pract Res Clin Rheumatol 27:1 (2013), 3–17.
3. [3] Katsuyama, T., Sada, K.E., Makino, H., Current concept and epidemiology of systemic vasculitides. Allergol Int 63:4 (2014), 505–513.
4. [4] Ozen, S., Pistorio, A., Iusan, S.M., Bakkaloglu, A., Herlin, T., Brik, R., et al. EULAR/PRINTO/PRES criteria for Henoch–Schönlein purpura, childhood polyarteritis nodosa, childhood Wegener granulomatosis and childhood Takayasu arteritis: Ankara 2008. Part II: Final classification criteria. Ann Rheum Dis 69:5 (2010), 798–806.
5. [5] Pharmacoepidemiological Research on Outcomes of Therapeutics by a European ConsorTium (PROTECT). The PROTECT database of all adverse drug reactions (ADRs) listed in the summary of product characteristics (SPC) of medicinal products authorized according to the centralized procedure, 2015 〈http://www.imi-protect.eu/adverseDrugReactions.shtml〉 (accessed on 21 January 2015).
6. [6] Hoffman, G.S., Calabrese, L.H., Vasculitis: determinants of disease patterns. Nat Rev Rheumatol 10:8 (2014), 454–462.
7. [7] Tseng, H.F., Sy, L.S., Liu, I.L., Qian, L., Marcy, S.M., Weintraub, E., et al. Postlicensure surveillance for pre-specified adverse events following the 13-valent pneumococcal conjugate vaccine in children. Vaccine 31:22 (2013), 2578–2583.
8. [8] Abrams, J.Y.W.E., Baggs, J.M., McCarthy, N.L., Schonberger, L.B., Lee, G.M., Klein, N.P., et al. Childhood vaccines and Kawasaki disease, vaccine safety datalink, 1996–2006. Vaccine 33:2 (2015), 382–387.
9. [9] Hunder, G.G., Arend, W.P., Bloch, D.A., Calabrese, L.H., Fauci, A.S., Fries, J.F., et al. The American College of Rheumatology 1990 criteria for the classification of vasculitis: introduction. Arthritis Rheum 33:8 (1990), 1065–1067.
10. [10] Jennette, J.C., Falk, R.J., Andrassy, K., Bacon, P.A., Churg, J., Gross, W.L., et al. Nomenclature of systemic vasculitides. Proposal of an international consensus conference. Arthritis Rheum 37:2 (1994), 187–192.
11. [11] Jennette, J.C., Falk, R.J., Bacon, P.A., Basu, N., Cid, M.C., Ferrario, F., et al. 2012 revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides. Arthritis Rheum 65:1 (2013), 1–11.
12. [12] Watts, R.A., Scott, D.G., Recent developments in the classification and assessment of vasculitis. Best Pract Res Clin Rheumatol 23:3 (2009), 429–443.
13. [13] Watts, R., Lane, S., Hanslik, T., Hauser, T., Hellmich, B., Koldingsnes, W., et al. Development and validation of a consensus methodology for the classification of the ANCA-associated vasculitides and polyarteritis nodosa for epidemiological studies. Ann Rheum Dis 66:2 (2007), 222–227.
14. [14] Ozen, S., Ruperto, N., Dillon, M.J., Bagga, A., Barron, K., Davin, J.C., et al. EULAR/PReS endorsed consensus criteria for the classification of childhood vasculitides. Ann Rheum Dis 65:7 (2006), 936–941.
15. [15] Abdulkader, R., Lane, S.E., Scott, D.G., Watts, R.A., Classification of vasculitis: EMA classification using CHCC 2012 definitions. Ann Rheum Dis, 72(11), 2013, 1888.
16. [16] The Brighton Collaboration, Vaccine safety quarterly (VSQ), vol. 1(9), 2014 〈https://brightoncollaboration.org/public/resources/newsletter/vsq-2014-q1.html〉 (accessed on 21 January 2015).
17. [17] The Brighton Collaboration. Standardized case definitions, 2015 〈https://brightoncollaboration.org/public/what-we-do/setting-standards/case-definitions.html〉 (accessed on 21 January 2015).
18. [18] The European Medicines Agency. 2013 annual report on EudraVigilance for the European Parliament, the Council and the Commission. EMA/145085/2014. 4 April 2014, The European Medicines Agency, London 〈http://www.ema.europa.eu/docs/en_GB/document_library/Report/2014/04/WC500165780.pdf〉 (accessed on 21 January 2015).
19. [19] The Centers for Disease Control and Prevention (CDC) and the Food and Drug Administration (FDA). The Vaccine Adverse Event Reporting System (VAERS). https://vaers.hhs.gov/about/index.(accessed on 21 January 2015).
20. [20] The Uppsala Monitoring Centre. Uppsala Reports 66. July 2014. http://www.who-umc.org/graphics/28198.pdf.(accessed on 21 January 2015).
21. [21] The International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use. ICH guidelines. Clinical Safety Data Management: Definitions and Standards for Expedited Reporting E2A. 27 October 1994. http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Efficacy/E2A/Step4/E2A_Guideline.pdf.(accessed on 21 January 2015).
22. [22] The International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use. The Medical Dictionary for Regulatory Activities (MedDRA) www.meddra.org.(accessed on 21 January 2015).
23. [23] The WHO Collaborating Centre for Drug Statistics Methodology. Oslo, Norway. http://www.whocc.no/atc_ddd_index/.(accessed on 21 January 2015).
24. [24] The International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use. The Medical Dictionary for Regulatory Activities (MedDRA). The MedDRA Hierarchy http://www.meddra.org/how-to-use/basics/hierarchy.(accessed on 21 January 2015).
25. [25] The International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use. The Medical Dictionary for Regulatory Activities (MedDRA). Introductory Guide for Standardised MedDRA Queries (SMQs) Version 17.0. http://www.meddra.org/sites/default/files/guidance/file/smq_intguide_17_0_english.pdf.(accessed on 21 January 2015).
26. [26] Oberle, D., Pönisch, C., Weißer, K., Keller-Stanislawski, B., Mentzer, D., Schutzimpfung gegen Rotavirusgastroenteritis. Assoziation mit dem Kawasaki-Syndrom?. Monatsschr Kinderheilkd 158:12 (2010), 1253–1260.
27. [27] Stassen, P.M., Sanders, J.S., Kallenberg, C.G., Stegeman, C.A., Influenza vaccination does not result in an increase in relapses in patients with ANCA-associated vasculitis. Nephrol Dial Transplant 23:2 (2008), 654–658 Official publication of the European Dialysis and Transplant Association–European Renal Association.
28. [28] Holvast, A., Stegeman, C.A., Benne, C.A., Huckriede, A., Wilschut, J.C., Palache, A.M., et al. Wegener's granulomatosis patients show an adequate antibody response to influenza vaccination. Ann Rheum Dis 68:6 (2009), 873–878.